Molecular Immunology from Promega
Peptide Antibody from Proteintech Group, Inc.
..., 1. Modular system for large format and medium th...t or precast gels (26 x 20 cm) simultaneously.Use ...to-use 1.0-mm or 1.5-mm pre-assembled hinged gel c...unloading.Built-in ceramic heat exchanger and buff...
ELF® 97 Immunohistochemistry Kit from Molecular Probes (Invitrogen)
Biology Products:(Date:11/19/2009)..., Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ... a randomized Phase 2B study of AEG35156, a target...for multiple oncology indications. ,, The study... of the X-Linked Inhibitor of Apoptosis (XIAP) Ant...e Cytarabine and Idarubicin in AML Following Failu...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies Form I...oordinate Best Practices in Risk Reduction ,Five...e Gene Synthesis Capacity , ...rsquo;s leading gene synthesis companies today ann...eening protocol to promote biosecurity in the gene...
(Date:11/19/2009)...VIENNA, Austria, November 19 AFFiR...n one product candidate at an unexpectedly early,s... planned to enter into,Phase II clinical trial ear...ly follows the completion of two Phase I trials wi... its fast decision on the first interim,analysis o...
(Date:11/18/2009)...National Institute of Standards and Technology (NI...ive method for detecting and measuring elusive haz...sible spoilage in food or pesticides distributed i...ore sensitive than conventional techniques for det...ike water molecules, having distinct electrically ...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Prototype NIST method detects and measures elusive hazards 2